Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults

被引:36
作者
Baxter, Roger [1 ]
Yee, Arnold [1 ]
Aukes, Laurie [1 ]
Snow, Vincenza [2 ]
Fireman, Bruce [1 ]
Atkinson, Bruce [2 ]
Klein, Nicola P. [1 ]
机构
[1] Kaiser Permanente Northern Calif, Vaccine Study Ctr, Oakland, CA USA
[2] Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA USA
关键词
Pneumococcal; Streptococcus pneumoniae; Invasive pneumococcal disease (IPD); Risk conditions; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; EPIDEMIOLOGY; CHILDREN; ERA; INFECTIONS;
D O I
10.1016/j.vaccine.2016.07.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: In the United States, the 13-valent pneumococcal conjugate vaccine is recommended in persons 65 years of age, and persons <= 65 years of age with immunocompromising (IC) conditions. For invasive pneumococcal disease (IPD) prevention in those <= 65 with non-IC medical conditions, the 23-valent polysaccharide vaccine is recommended. This group is at higher risk of IPD than the general population, but the level of risk is not well-quantified. We estimated IPD risk by individual underlying medical conditions, and by total number of conditions, for persons 18 years of age. We calculated the relative risks (RR) of various medical conditions, comparing the incident IPD cases to the general study population, and used Poisson regression models to estimate an IPD RR, adjusting for other conditions. We also examined IPD incidence by number of conditions diagnosed in each calendar year, using a risk-stacking model. Results: Underlying medical conditions with the highest adjusted RR for IPD were chronic liver disease (RR 2.1, 95% CI 1.5-2.8) and chronic obstructive pulmonary disease (COPD; RR 2.1, 95% CI 1.8-2.5). IPD risk increased with increasing number of medical conditions: adjusted RR, 2.2 (95% CI 1.9-2.5) 1 condition, 2.9 (2.5-3.5) for 2 conditions, and 5.2 (4.4-6.1) for 3 conditions. Conclusions: For persons with a single, non-IC medical condition, IPD risk was twice that for the general KPNC population. Persons with multiple, non-IC chronic conditions exhibited increased IPD risk with each additional condition. Such information may inform discussions on recommendations for adult pneumococcal immunization and prevention. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4293 / 4297
页数:5
相关论文
共 16 条
  • [1] The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era A Case for Continuous Surveillance
    Ampofo, Krow
    Pavia, Andrew T.
    Stockmann, Chris
    Hersh, Adam L.
    Bender, Jeffrey M.
    Blaschke, Anne J.
    Weng, Hsin Yi Cindy
    Korgenski, Kent E.
    Daly, Judy
    Mason, Edward O.
    Byington, Carrie L.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (03) : 228 - 234
  • [2] Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence
    Curcio, Daniel
    Cane, Alejandro
    Isturiz, Raul
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 37 : 30 - 35
  • [3] Demczuk WHB, 2012, CAN J MICROBIOL, V58, P1008, DOI [10.1139/w2012-073, 10.1139/W2012-073]
  • [4] Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults
    Flory, J. H.
    Joffe, M.
    Fishman, N. O.
    Edelstein, P. H.
    Metlay, J. P.
    [J]. EPIDEMIOLOGY AND INFECTION, 2009, 137 (05) : 717 - 726
  • [5] Nearly Complete Elimination of the 7-valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee
    Halasa, Natasha B.
    Grijalva, Carlos G.
    Arbogast, Patrick G.
    Talbot, Thomas R.
    Craig, Allen S.
    Griffin, Marie R.
    Schaffner, William
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (06) : 604 - 609
  • [6] Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine
    Kaplan, Sheldon L.
    Barson, William J.
    Lin, Philana Ling
    Romero, Jose R.
    Bradley, John S.
    Tan, Tina Q.
    Hoffman, Jill A.
    Givner, Laurence B.
    Mason, Edward O., Jr.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (03) : 203 - 207
  • [7] Have changing pneumococcal vaccination programmes impacted disease in Ontario?
    Lim, Gillian H.
    Wormsbecker, Anne E.
    McGeer, Allison
    Pillai, Dylan R.
    Gubbay, Jonathan B.
    Rudnick, Wallis
    Low, Don E.
    Green, Karen
    Crowcroft, Natasha S.
    Deeks, Shelley L.
    [J]. VACCINE, 2013, 31 (24) : 2680 - 2685
  • [8] Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults
    Morrill H.J.
    Caffrey A.R.
    Noh E.
    LaPlante K.L.
    [J]. Infectious Diseases and Therapy, 2014, 3 (1) : 19 - 33
  • [9] Muhammad Riyadh D, 2013, Clin Infect Dis, V56, pe59, DOI 10.1093/cid/cis971
  • [10] Risk of Pneumococcal Disease in Children With Chronic Medical Conditions in the Era of Pneumococcal Conjugate Vaccine
    Pelton, Stephen I.
    Weycker, Derek
    Farkouh, Raymond A.
    Strutton, David R.
    Shea, Kimberly M.
    Edelsberg, John
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 (05) : 615 - 623